Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

The epidemiological trends and projected future of primary sclerosing cholangitis by 2040: An updated meta-analysis and modeling study

View through CrossRef
Background and Aims Primary sclerosing cholangitis (PSC) exhibits varying incidence and prevalence rates across different regions; however, comprehensive global studies examining its geographic distribution and future trends are scarce. This study presents an updated meta-analysis through 2024 and projects the global and regional prevalence of PSC from 2024 to 2040 using an illness-death multi-state model. Methods We conducted a thorough systematic search across multiple databases to identify all primary studies published until 2024 that reported on the incidence, prevalence, and mortality rates of PSC in various regions. Using the gathered data, we developed an illness-death model to forecast the future prevalence of PSC, covering the years 2024–2040. Results Our meta-analysis revealed that the global pooled incidence and prevalence rates of PSC are 0.65 and 7.52 per 100,000 persons, respectively. Projections indicate that the global prevalence of PSC will rise to 22.98 cases per 100,000 (95% CI: 21.0–24.95), corresponding to an overall increase of 28.3%. Specifically, North America is forecasted to experience a 5.45% increase in PSC cases, reaching 24.76 cases per 100,000 (95% CI: 19.63–29.88), while Western Europe is anticipated to see a more pronounced rise of 28.79%, resulting in a prevalence of 21.48 cases per 100,000 (95% CI: 18.3–24.65) by 2040. Conclusions Our findings indicate a substantial rise in the number of individuals affected by PSC in recent years and estimate a significant future burden of the disease.
Title: The epidemiological trends and projected future of primary sclerosing cholangitis by 2040: An updated meta-analysis and modeling study
Description:
Background and Aims Primary sclerosing cholangitis (PSC) exhibits varying incidence and prevalence rates across different regions; however, comprehensive global studies examining its geographic distribution and future trends are scarce.
This study presents an updated meta-analysis through 2024 and projects the global and regional prevalence of PSC from 2024 to 2040 using an illness-death multi-state model.
Methods We conducted a thorough systematic search across multiple databases to identify all primary studies published until 2024 that reported on the incidence, prevalence, and mortality rates of PSC in various regions.
Using the gathered data, we developed an illness-death model to forecast the future prevalence of PSC, covering the years 2024–2040.
Results Our meta-analysis revealed that the global pooled incidence and prevalence rates of PSC are 0.
65 and 7.
52 per 100,000 persons, respectively.
Projections indicate that the global prevalence of PSC will rise to 22.
98 cases per 100,000 (95% CI: 21.
0–24.
95), corresponding to an overall increase of 28.
3%.
Specifically, North America is forecasted to experience a 5.
45% increase in PSC cases, reaching 24.
76 cases per 100,000 (95% CI: 19.
63–29.
88), while Western Europe is anticipated to see a more pronounced rise of 28.
79%, resulting in a prevalence of 21.
48 cases per 100,000 (95% CI: 18.
3–24.
65) by 2040.
Conclusions Our findings indicate a substantial rise in the number of individuals affected by PSC in recent years and estimate a significant future burden of the disease.

Related Results

Granulomas in primary sclerosing cholangitis
Granulomas in primary sclerosing cholangitis
Abstract: Granulomas in liver biopsy specimens from adult patients with chronic ductopenic cholestatic liver disease are a characteristic feature of primary biliary cirrhosis. How...
Clinical Criteria and Operative Complications of Complicated Cholangitis
Clinical Criteria and Operative Complications of Complicated Cholangitis
Introduction: Complicated cholangitis is a severe bacterial infection of the bile ducts that often occurs in patients with biliary obstruction. The condition is characterized by a ...
Autoimmune Hepatitis/Overlap Syndromes
Autoimmune Hepatitis/Overlap Syndromes
When autoimmune hepatitis has features of primary biliary cholangitis or primary sclerosing cholangitis, these mixed clinical phenotypes constitute overlap syndromes. Diagnostic cr...
Autoimmune Hepatitis/Overlap Syndromes
Autoimmune Hepatitis/Overlap Syndromes
When autoimmune hepatitis has features of primary biliary cholangitis or primary sclerosing cholangitis, these mixed clinical phenotypes constitute overlap syndromes. Diagnostic cr...
Risk Factors, Physicians’ Practice and Outcomes of Post-Kasai Cholangitis
Risk Factors, Physicians’ Practice and Outcomes of Post-Kasai Cholangitis
Abstract Background Extra hepatic biliary atresia (EHBA) is the most common cause of neonatal cholestasis. Kasai operatio...

Back to Top